REG - N4 Pharma PLC - Grant of Options
RNS Number : 2516NN4 Pharma PLC18 May 202018 May 2020
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Grant of Options
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces the Company has today granted 1,434,286 options (the "Options") over ordinary shares of 0.4 pence in the Company ("Ordinary Shares") to certain Directors of the Company. These Options have been granted pursuant to the Company's Unapproved Share Option Scheme, as follows:
Director
Number of Options granted
Existing options over Ordinary Shares held
Total Options over Ordinary Shares held following grant
David Templeton Executive Director
717,143
717,143
1,434,286
Luke Cairns
Non-Executive Director
717,143
1,392,445
2,109,588
The Options have an exercise price of 4.8 pence per Option, being the closing mid-market price of an Ordinary Share on 15 May 2020, the business day prior to the grant. The Options can be exercised from three years from the grant date and up to the tenth anniversary of the grant date, provided that the individual remains an employee of the Company. Following the grant of the Options, the Company has options in issue over a total of 8,396,513 Ordinary Shares, representing 8.28 per cent. of the Company's current issued share capital, or 5.52 per cent. of the Company's issued share capital as enlarged by the placing announced on 13 May 2020.
The FCA notifications, made in accordance with the requirements of the EU Market Abuse Regulation, are appended below.
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO
Via Scott PR
Allenby Capital Limited
James Reeve/Asha Chotai
Tel: +44(0)203 328 5656
Scott PR
Georgia Smith
Tel: +44(0)1477 539 539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
David Templeton
2
Reason for the notification
a)
Position/status
Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
N4 Pharma plc
b)
LEI
213800I841D2RKMFK955
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Options over Ordinary Shares of 0.4p each
Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32
b)
Nature of the transaction
Issue of options over ordinary shares of 0.4p each
c)
Price(s) and volume(s)
Price(s)
Volume(s)
4.8p exercise price
717,143
d)
Aggregated information
- Aggregated volume
- Price
n/a
e)
Date of the transaction
18 May 2020
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Luke Cairns
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
N4 Pharma plc
b)
LEI
213800I841D2RKMFK955
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Options over Ordinary Shares of 0.4p each
Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32
b)
Nature of the transaction
Issue of options over ordinary shares of 0.4p each
c)
Price(s) and volume(s)
Price(s)
Volume(s)
4.8p exercise price
717,143
d)
Aggregated information
- Aggregated volume
- Price
n/a
e)
Date of the transaction
18 May 2020
f)
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDDSHAPMATMTTBBMM
Recent news on N4 Pharma
See all newsREG - N4 Pharma PLC - Posting of Annual Report & Notice of AGM
AnnouncementRCS - N4 Pharma PLC - N4 Pharma Webinar on SRI Collaboration
AnnouncementREG - N4 Pharma PLC - Collaboration Agreement with SRI International Inc
AnnouncementREG - N4 Pharma PLC - Final Results
AnnouncementREG - N4 Pharma PLC - Oral Delivery Update
Announcement